Table 4.
Surgery for recurrent hepatocellular carcinoma after liver transplantation
| No. resection/total (%) | Site of resection |
Median OS in months |
Selection criteria | Resection: Independent predictor of survival | ||
| Overall | Resection/no resection | |||||
| Comparative study | ||||||
| Roayaie et al[4], 2004 | 18/57 (31.6) | Liver (n = 8), lung (n = 7), adrenal (n = 2), chest wall (n = 1)1 | 8.7 | - | Technical feasibility | Yes |
| Kornberg et al[76], 2010 | 7/16 (43.8) | Liver (n = 2), lung (n = 2), others (n = 3) | 10.5 | 65/55 | - | Yes |
| Valdivieso et al[39], 2010 | 11/23 (47.8) | Liver (n = 2), lung (n = 2), adrenal (n = 2), abdominal lymph node (n = 2) | - | 32.3 ± 21.5/11.9 ± 6.925 | Technical feasibility | - |
| Sapisochin et al[77], 2015 | 38/121 (31.4) | - | - | 31/12/535 | Technical feasibility | Yes |
| Bodzin et al[78], 2017 | 25/106 (23.6) | lung (n = 8), bone (n = 6), intra-abdominal (n = 4), liver (n = 3), brain (n = 2) | 10.6 | 27.8/10.6/3.735 | - | - |
| Fernandez-Sevilla et al[79], 2017 | 22/70 (31.4)4 | - | 19 | 35/155 | Technical feasibility. No progression with systemic treatment | Yes |
1
Include radiofrequency ablation of liver lesion (n = 2);
2
R0 resection vs no R0 resection;
3
Resection vs non-surgical treatment vs best supportive care;
4
R0/1 resection vs no R0/1 resection;
5
Statistically significant. OS: Overall survival.